Alberto Chiappori, MD
Dr. Alberto A. Chiappori is a medical and thoracic oncologist at the Moffitt Cancer Center and Research Institute in Tampa, Florida. He is a Senior Member of Oncology and Medicine for the Thoracic Oncology Program. He specializes in treating patients diagnosed with lung cancers and malignant pleural mesothelioma, as well as pleural neoplasms.[1]
Dr. Chiappori works extensively with immunotherapy and updated forms of chemotherapy in treating patients with these challenging conditions. He is optimistic that anti-PD-L1 checkpoint inhibitors and other new drugs will make a significant improvement in overall survival and patient safety. He also believes that advances in genomic testing have made significant contributions to the understanding of cancers and their subtypes and their sensitivity to different drugs.[2]
Education and Career
Dr. Chiappori earned his medical degree at the Universidad Peruana Cayetano Heredia in Lima, Peru. He then completed an internship and residency in Internal Medicine at Southern Illinois University School of Medicine in Springfield, Illinois, and a fellowship and senior fellowship in Medical Oncology and Hematology at Vanderbilt University School of Medicine in Nashville, Tennessee. He is board-certified in Medical Oncology.[1]
Professional Memberships and Activities
Dr. Chiappori is an active member of the American Society of Clinical Oncology and the International Association for the Study of Lung Cancer.[1]
Dr. Chiappori is currently participating in the following clinical trials:[1]
Clinical Trial 19836
REPLATINUM: A Phase 3, Controlled, Open-label,Randomized Study of RRx-001 Administered Sequentially with a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Lung Cancer
Condition: Thoracic
Intervention: Paraplatin (carboplatin); RRx-001 (); carboplatin (); cisplatin (); etoposide ()
Status: Open
Clinical Trial 20938
A Randomized Phase II Trial of Adjuvant Pembrolizumab Versus Observation Following Curative Resection for Stage I Non-Small Cell Lung Cancer (NSCLC) with Primary Tumors Between 1-4 cm
Condition: Thoracic
Intervention: Not Applicable (); Pembrolizumab (Keytruda)
Status: Open
Clinical Trial 21852
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating Efficacy and Safety of Inupadenant in Combination with Carboplatin and Pemetrexed in Adults with Nonsquamous Non-Small Cell Lung Cancer Who Have Progressed on Immunotherapy
Condition: Thoracic
Intervention: Alimta (Pemetrexed); Inupadenant HCl (); Paraplatin (carboplatin); Pemetrexed (); Placebo (); carboplatin ()
Status: Open
Clinical Trial 22092
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib (MK-7339), Compared to Concurrent Chemoradiation Therapy Alone in Participants with Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC).
Condition: Thoracic
Status: Open
Clinical Trial 22196
A First in Human Dose Escalation and Cohort Expansion Study of DLL3-directed Chimeric Antigen Receptor T-cells in Subjects with Extensive Stage Small Cell Lung Cancer
Condition: Thoracic
Intervention: LB2102 (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Status: Open
His recent publications include:[1]
- Saltos AN, Creelan BC, Tanvetyanon T, Chiappori AA, Antonia SJ, Shafique MR, Ugrenovic-Petrovic M, Sansil S, Neuger A, Ozakinci H, Boyle TA, Kim J, Haura EB, Gray JE. A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC harboring activating KRAS or EGFR mutations. Lung Cancer. 2023 Sep.183:107313. Pubmedid: 37499521.
- Gilardone S, Thapa R, Laborde J, Shafique M, Saltos A, Creelan B, Tanvetyanon T, Chiappori A, Simon G, Haura EB, Gray JE, Chen DT, Melzer D, Pellini B. Osimertinib vs. afatinib as first-line treatment for patients with metastatic non-small cell lung cancer with an EGFR exon 19 deletion or exon 21 L858R mutation. J Thorac Dis. 2023 Nov.15(11):6115-6125. Pubmedid: 38090314. Pmcid: PMC10713299.
- Liveringhouse CL, Latifi K, Asous AG, Lam NB, Rosenberg SA, Dilling TJ, MacMillan GV, Chiappori AA, Haura EB, Creelan B, Gray JE, Tanvetyanon T, Shafique MR, Saltos AN, Weiner AA, Clarke J, Kelsey CR, Kim S, Caudell JJ, Rose TA, Conejo-Garcia JR, Li J, Schell MJ, Antonia SJ, Perez BA. Dose-Limiting Pulmonary Toxicity in a Phase 1/2 Study of Radiation and Chemotherapy with Ipilimumab Followed by Nivolumab for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2023 Jul.116(4):837-848. Pubmedid: 36657497.
- Aix SP, Ciuleanu TE, Navarro A, Cousin S, Bonanno L, Smit EF, Chiappori A, Olmedo ME, Horvath I, Grohé C, Farago AF, López-Vilariño JA, Cullell-Young M, Nieto A, Vasco N, Gómez J, Kahatt C, Zeaiter A, Carcereny E, Roubec J, Syrigos K, Lo G, Barneto I, Pope A, Sánchez A, Kattan J, Zarogoulidis K, Waller CF, Bischoff H, Juan-Vidal O, Reinmuth N, Dómine M, Paz-Ares L. Combination lurbinectedin and doxorubicin versus physician’s choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial. Lancet Respir Med. 2023 Jan.11(1):74-86. Pubmedid: 36252599.
- Marin-Acevedo JA, Pellini B, Kimbrough EO, Hicks JK, Chiappori A. Treatment Strategies for Non-Small Cell Lung Cancer with Common EGFR Mutations: A Review of the History of EGFR TKIs Approval and Emerging Data. Cancers (Basel). 2023 Jan.15(3). Pubmedid: 36765587. Pmcid: PMC9913773.
- Dudek AZ, Xi MX, Scilla KA, Mamdani H, Creelan BC, Saltos A, Tanvetyanon T, Chiappori A. Phase 2 Trial of Nivolumab and Ramucirumab for Relapsed Mesothelioma: HCRN-LUN15-299. JTO Clin Res Rep. 2023 Dec.4(12):100584. Pubmedid: 38046376. Pmcid: PMC10689266.
- Chen DT, Saltos AN, Rose T, Thompson ZJ, Thapa R, Chiappori A, Gray JE. Early Adverse Event Derived Biomarkers in Predicting Clinical Outcomes in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy. Cancers (Basel). 2023 Apr.15(9). Pubmedid: 37173987. Pmcid: PMC10177532.
- Hamid O, Chiappori AA, Thompson JA, Doi T, Hu-Lieskovan S, Eskens FALM, Ros W, Diab A, Spano JP, Rizvi NA, Wasser JS, Angevin E, Ott PA, Forgie A, Yang W, Guo C, Chou J, El-Khoueiry AB. First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors. J Immunother Cancer. 2022 Oct.10(10). Pubmedid: 36302562. Pmcid: PMC9621185.
